RCT | Ripretinib vs. Sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib.
8 Sep, 2022 | 14:24h | UTC
Commentary on Twitter
? INTRIGUE Trial: Ipretinib not superior to sunitinib but demonstrates longest median progression free survival ever in advanced #GastrointestinalStromalTumor ➡️ https://t.co/aUNdvXaQcH #GIST #scmsm @seppobauer pic.twitter.com/pPfph6A8Lr
— Journal of Clinical Oncology (@JCO_ASCO) August 24, 2022